Loading...
Oxford Nanopore Technologies plc
ONTTF•PNK
Healthcare
Biotechnology
$2.85
$0.01(0.35%)

The company's financials show resilient growth, with revenue advancing from $86.002M in Q2 2023 to $84.08M in Q2 2024. Gross profit remained healthy with margins at 59% in Q2 2024 compared to 58% in Q2 2023. Operating income hit -$77.02M last quarter, sustaining a consistent -92% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$70.24M. Net income rose to -$74.65M, while earnings per share reached -$0.09. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan